Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Type I interferon receptor complex is a heterodimeric membrane receptor consisting of IFNAR1 and IFNAR2 subunits. Both subunits belong to the class II cytokine receptor family and feature extracellular ligand binding domains, transmembrane regions, and cytoplasmic signaling domains. Upon binding type I interferons (including IFN-α and IFN-β), IFNAR1 and IFNAR2 dimerize and activate the JAK-STAT signaling pathway. This leads to transcriptional activation of hundreds of interferon-stimulated genes conferring antiviral protection, immune modulation, and anti-proliferative effects. The complex is targeted therapeutically in viral infection, cancer, and certain autoimmune conditions
Ligand binding (IFN-α or IFN-β) triggers heterodimerization of IFNAR1 and IFNAR2 - Activation of JAK1 and TYK2 kinases - Phosphorylation and dimerization of STAT proteins - Induction of transcription of interferon-stimulated genes, leading to antiviral and immunomodulatory effects
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Type I interferon receptor (IFNAR) complex (IFNAR (complex); IFNAR1 and IFNAR2 (subunits)).